Cyclandelate in the treatment of cerebral arteriosclerosis.

Cyclandelate in the treatment of cerebral arteriosclerosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cyclandelate in the treatment of cerebral arteriosclerosis. Abstract Text:

Twenty-one patients with cerebral arteriosclerosis were treated for twelve months with placebo or cyclandelate (Cyclospasmol), 400 mg four times daily, in a double-blind study with medication cross-over after six months. The group included 8 men and 13 women, with a mean age of 69 years. Each patient showed at least 5 of 9 signs or symptoms adopted as "inclusion criteria" for the study. Concomitant psychotropic or other drug therapy was standardized or matched during the trial, and periodic assessments were made of the patients' behavioral, physical, neurologic and psychiatric status. No serious side effects were observed. There was no significant difference between the cyclandelate and placebo phases in measurements of physical state. Changes on the gross behavior scales were insufficient for analysis. Tests of memory, control of manual dexterity and comprehension of everyday situations showed statistically significant improvement during the cyclandelate phase. In contrast to placebo, no measurable intellectual decline occurred during cyclandelate therapy.

Cyclandelate in the treatment of cerebral arteriosclerosis. Publishing Authors By Initials

For similar pharmaceutical preparations: placebos research abstracts see: pharmaceutical preparations: placebos research

PUBMED ID PMID:

MEDLINE DATE:

Cyclandelate in the treatment of cerebral arteriosclerosis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of the American Geriatrics Society

VOLUME: 24

Page Numbers: 41-5

Journal Abbreviation: J Am Geriatr Soc

ISSN: 0002-8614

DAY: 10

MONTH: Jan

YEAR: 1976

Cyclandelate in the treatment of cerebral arteriosclerosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7503062

Cyclandelate in the treatment of cerebral arteriosclerosis. Keywords Mesh Terms:

KEYWORDS: Placebos

MESH TERMS: drug effects

Chemical & Substance for Abstract: Cyclandelate in the treatment of cerebral arteriosclerosis. Information

Substance Name: Cyclandelate

Registry Number: 456-59-7

Grant and Affiliation Information for Cyclandelate in the treatment of cerebral arteriosclerosis.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Am Geriatr Soc

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cyclandelate in the treatment of cerebral arteriosclerosis Related Publications

• A comparison of Ki67 immunostaining and nucleolar organiser region staining in non-Hodgkin's lymphoma. P. A. Hall, J. Crocker, A. Watts, A. G. Stansfeld. Histopathology 1988; 12; 373-381 &.
• A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases.
• A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-kappaB signalling pathways.
• A summary of recommendations for the management of opioid dependence: the quality assurance in the treatment of drug dependence project.
• AQP0-LTR of the Cat Fr mouse alters water permeability and calcium regulation of wild type AQP0.
• Activation of G1 progression, JNK mitogen-activated protein kinase, and actin filament assembly by the exchange factor FGD1.
• Activin and bone morphogenetic proteins induce calcitonin gene-related peptide in embryonic sensory neurons in vitro.
• Editorial.
• Effect of cartilage oligomeric matrix protein on mesenchymal chondrogenesis in vitro.
• Effect of nutrition on the LH response to calf removal and GnRH.
• Efficient chondrogenic differentiation of mesenchymal cells in micromass culture by retroviral gene transfer of BMP-2.
• Gene expression profiling following BMP-2 induction of mesenchymal chondrogenesis in vitro.
• In-situ hydration studies using multi-angle energy-dispersive diffraction.
• International studies in dementia with particular emphasis on populations of African origin.
• Investigations of the incidence of bovine trichomoniasis in nevada and of the efficacy of immunizing cattle with vaccines containing Tritrichomonas foetus.
• Is ultrasound useful for evaluating paediatric inflammatory neck masses?
• Laparoscopic transfer of ovine and cervine embryos using the transpic technique.
• Nonword repetition skills in young children who do and do not stutter.
• Oxygen cathode measurements and radiation response in tumour-bearing mice treated with misonidazole.
• Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade.
• Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16.
• Reduced expression of endothelin B receptors and mechanical hyperalgesia in experimental chronic diabetes.
• Spontaneous formation of annular structures observed in molecular dynamics simulations of polyglutamine peptides.
• Systems approaches to biological rhythms in Drosophila.
• The effectiveness of methadone maintenance treatment: an overview.
• The use of derivative and least-squares methods to analyse a polypharmaceutical product by UV spectrophotometry.
• Validation analysis of informant's ratings of cognitive function in African Americans and Nigerians.
• Viral Load and Neuropsychological Functioning in HIV Seropositive Individuals:A Preliminary Descriptive Study.
• [In Process Citation]
• [In Process Citation]